GlassScriptPhysician profile
Erik J Pieramici
NPI 1710091954
$5,048.46
in general payments reported to CMS, 2019-2025
28 companies · $738 in 2025
The $738 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $322 · 2020: $125 · 2021: $283 · 2022: $989 · 2023: $1,286 · 2024: $1,305 · 2025: $738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,329.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,978.97 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $750.42 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Gilead Sciences, INC. | $441.04 | 2019-2025 | |
| Celgene Corporation | $307.32 | 2022-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $262.51 | 2022-2024 | Xifaxan, Trulance |
| Regeneron Healthcare Solutions, INC. | $183.94 | 2023-2025 | Dupixent |
| Janssen Biotech, INC. | $148.62 | 2019-2025 | Stelara, Simponi, Remicade |
| Ironwood Pharmaceuticals, INC | $115.51 | 2019-2022 | |
| Intercept Pharmaceuticals, INC. | $111.40 | 2019-2024 | Ocaliva |
| Ardelyx, INC. | $101.83 | 2023-2025 | Ibsrela |
| Pfizer INC. | $96.59 | 2019-2025 | |
| Genzyme Corporation | $91.63 | 2023-2024 | |
| Lilly USA, LLC | $72.90 | 2023-2024 | Omvoh |
| Qol Medical, LLC | $70.55 | 2021-2024 | Sucraid |
| Axonics, INC. | $53.69 | 2024 | Axonics |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $40.32 | 2023-2024 | Rebyota |
| Braintree Laboratories, INC. | $28.16 | 2021-2022 | |
| Allergan, INC. | $24.61 | 2019 | |
| Daiichi Sankyo INC. | $20.04 | 2022 | |
| Alnylam Pharmaceuticals INC. | $19.43 | 2021 | |
| Olympus America INC. | $18.26 | 2022 | |
| Mirum Pharmaceuticals, INC. | $17.78 | 2024 | Livmarli |
| Novo Nordisk INC | $17.18 | 2025 | Wegovy |
| Ucb, INC. | $16.36 | 2020 | |
| Nestle Healthcare Nutrition INC. | $15.93 | 2021 | |
| Ethicon US, LLC | $15.08 | 2020 | |
| Organon LLC | $14.60 | 2025 | Renflexis, Hadlima |
| Phathom Pharmaceuticals, INC. | $13.79 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erik Pieramici listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.